TD Cowen initiated coverage of Immatics (IMTX) with a Buy rating and no price target The firm says the company has the most extensive PRAME-targeted pipeline. Immatics’ lead asset is anzu-cel, a TCR T-cell therapy with a “low-risk” Phase III readout in the second half of 2026, the analyst tells investors in a research note. TD sees potentially superior efficacy, no surgical resection, and rapid 14-day manufacturing versus Amtagvi.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMTX:
- Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO
- Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion
- Immatics abstract accepted for late-breaking poster presentation at AACR meeting
- Immatics assumed with a Buy at Jefferies
- Immatics Confirms 2027 Anzu-cel Launch Timeline as PRAME Franchise and Cash Runway Advance